Global Oral Iron Therapy for Anemia Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

Oral Iron Therapy for Anemia Market Size

• The global oral iron therapy for anemia market was valued at USD 2.19 billion in 2024 and is expected to reach USD 4.62 billion by 2032
• During the forecast period of 2025 to 2032 the market is likely to grow at a CAGR of 9.80%, primarily driven by the rising anemia prevalence and advancements
• This growth is driven by factors such as rising prevalence of iron deficiency anemia and shift towards non-invasive and patient-friendly treatments

Oral Iron Therapy for Anemia Market Analysis

• Oral iron therapy for anemia refers to the administration of iron supplements in oral form to treat iron deficiency anemia and other related conditions. These therapies are widely used due to their convenience, affordability, and effectiveness in replenishing iron stores in the body
• The global oral iron therapy market is experiencing significant growth, driven by the rising prevalence of anemia, particularly among pregnant women, children, and individuals with chronic diseases
• In addition, increasing awareness about iron deficiency and the availability of advanced formulations with better absorption and fewer gastrointestinal side effects are contributing to market expansion
• The market is further supported by government initiatives and nutrition programs aimed at addressing anemia worldwide 
• For instance, in October 2023, the World Health Organization (WHO) launched a global campaign to reduce anemia prevalence through enhanced dietary interventions and supplementation programs. Moreover, pharmaceutical companies are focusing on innovative drug formulations, such as liposomal iron and polysaccharide iron complexes, to improve patient compliance
• Despite these advancements, challenges such as side effects, poor adherence, and competition from intravenous iron therapies remain. However, ongoing research and the development of novel drug delivery methods are expected to enhance the efficacy of oral iron therapies, driving future market growth

Report Scope and Oral Iron Therapy for Anemia Market Segmentation        

Oral Iron Therapy for Anemia Market Trends

“Development of Advanced Formulations with Improved Bioavailability”

• One prominent trend in the oral iron therapy for anemia market is the development of advanced formulations with improved bioavailability and fewer side effects. Traditional iron supplements often cause gastrointestinal discomfort, leading to poor patient compliance
• To address this, pharmaceutical companies are focusing on innovative formulations such as liposomal iron, heme iron polypeptides, and polysaccharide iron complexes, which enhance absorption while reducing adverse effects such as constipation and nausea 
• For instance, in September 2023, a study published in the Journal of Clinical Medicine highlighted that liposomal iron supplements showed 30% higher absorption rates compared to conventional ferrous sulfate, with fewer reported side effects
• This shift towards patient-friendly formulations is expected to drive market growth, making oral iron therapy more accessible and effective for individuals suffering from anemia

Oral Iron Therapy for Anemia Market Dynamics

Driver

“Rising Prevalence of Iron Deficiency Anemia”

• The increasing prevalence of iron deficiency anemia worldwide is significantly contributing to the growing demand for oral iron therapy. Iron deficiency anemia is the most common form of anemia, affecting millions due to poor dietary intake, chronic diseases, and pregnancy-related iron depletion
• Women, children, and elderly populations are particularly at risk, leading to a higher need for effective and accessible iron supplementation
• The increasing awareness of anemia’s health impact, along with government initiatives promoting iron supplementation, is further fueling market growth
• Pharmaceutical companies are introducing innovative oral iron formulations with better absorption and fewer side effects, improving treatment adherence

For instance,

• In August 2023, according to a study published in The Lancet, global anemia cases surged due to nutritional deficiencies, with over 30% of women of reproductive age affected, highlighting the urgent need for better iron supplementation strategies
• In March 2024, the World Health Organization (WHO) launched a campaign promoting oral iron fortification programs to reduce global anemia rates, emphasizing the importance of accessible and cost-effective treatments 
• As a result of the rising prevalence of iron deficiency anemia, the demand for oral iron therapy continues to grow, ensuring better treatment outcomes and improving global health

Opportunity

“Development of Novel Iron Formulations Enhancing Treatment Efficiency”

• The introduction of novel oral iron formulations with enhanced bioavailability and fewer side effects is creating significant growth opportunities in the market
• Traditional iron supplements often cause gastrointestinal issues such as constipation and nausea, leading to poor patient compliance
• Newer formulations such as liposomal iron, ferric maltol, and sucrosomial iron offer better absorption, reduced side effects, and improved patient adherence, making them a preferred choice for anemia treatment

For instance,

• In February 2024, according to an article published in the British Journal of Haematology, liposomal iron supplements demonstrated 40% higher absorption compared to conventional ferrous sulfate, with significantly fewer gastrointestinal side effects, improving patient compliance
• In September 2023, a leading pharmaceutical company launched an advanced polysaccharide iron complex, aimed at improving tolerability and efficacy, further expanding treatment options for anemia patients

• The development of innovative oral iron formulations is expected to drive market growth, making anemia treatment more effective and accessible for a broader population

Restraint/Challenge

“Gastrointestinal Side Effects Limiting Patient Compliance”

• One of the major restraints in the oral iron therapy for anemia market is the prevalence of gastrointestinal side effects, which significantly impact patient adherence to treatment
• Common side effects, including nausea, constipation, diarrhea, and stomach pain, lead to poor compliance, resulting in treatment discontinuation or irregular dosage intake
• This challenge is particularly concerning for pregnant women and elderly patients, who often struggle with tolerating traditional iron supplements

For instance,

• In October 2023, according to a study published in the Journal of Clinical Pharmacology, over 30% of anemia patients discontinued oral iron therapy due to severe gastrointestinal discomfort, highlighting the need for better-tolerated formulations
• In June 2024, researchers at a leading pharmaceutical institute emphasized the demand for low-dose, high-absorption iron supplements to reduce side effects and improve patient adherence

• Consequently, these side effects pose a challenge to market expansion, requiring manufacturers to develop more tolerable and effective formulations to enhance treatment success

Oral Iron Therapy for Anemia Market Scope

The market is segmented on the basis of oral iron supplementation, age group, and end-user.

Oral Iron Therapy for Anemia Market Regional Analysis

“North America is the Dominant Region in the Oral Iron Therapy for Anemia Market”

• North America is the dominant region in the global oral iron therapy for anemia market, primarily due to the high prevalence of iron deficiency anemia (IDA), well-established healthcare infrastructure, and strong pharmaceutical research and development
• The region benefits from increased awareness programs, government initiatives, and advanced iron supplementation therapies that enhance patient compliance and treatment efficacy
• The presence of leading pharmaceutical companies investing in innovative formulations, such as liposomal iron and ferric maltol, has further strengthened the market. In addition, the growing elderly population, high anemia incidence in pregnant women, and chronic disease patients contribute to the increasing demand for oral iron therapy
• U.S. dominates the oral iron therapy for anemia market, driven by advanced healthcare infrastructure, high anemia prevalence, and strong pharmaceutical innovation
• Easy access to advanced healthcare facilities and reimbursement policies also plays a crucial role in maintaining North America's dominance in the global market

“Asia-Pacific is Projected to Register the Highest Growth Rate”

• Asia-Pacific is expected to register the highest growth rate in the global oral iron therapy for anemia market, driven by rising anemia prevalence, increasing healthcare awareness, and improving access to medical treatments. Countries such as India, China, and Japan are witnessing a surge in iron deficiency anemia cases due to poor dietary habits, high population density, and growing cases of chronic diseases
• India is projected to register the highest growth rate, driven by high anemia prevalence, growing healthcare access, and government nutrition initiatives
• Government initiatives and nutrition programs aimed at reducing anemia, along with rising healthcare investments and the expansion of pharmaceutical companies, are further fueling market growth. In addition, the increasing demand for cost-effective and patient-friendly oral iron formulations is boosting adoption
• With enhanced healthcare infrastructure, economic growth, and a rising focus on preventive care, Asia-Pacific is expected to experience the fastest expansion in the oral iron therapy market

Oral Iron Therapy for Anemia Market Share

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

The Major Market Leaders Operating in the Market Are:

• American Regent, Inc. (U.S.)
• CSL (Australia)
• Criticine Care (India)
• DAIICHI SANKYO COMPANY, LIMITED (Japan)
• Emcure Pharmaceuticals Limited (India)
• Fresenius Kabi AG (Germany)
• Farlex (India)
• Janus Biotech (India)
• Kye Pharmaceuticals (Canada)
• Lupin (India)
• Matinspharma (India)
• Novolilly Pharmaceutical (India)
• NIPPON SHINYAKU CO., LTD. (Japan)
• PHARMACOSMOS A/S (Denmark )
• Shield Therapeutics plc (U.K.)
• Sandoz Group AG (Switzerland)
• Somacare (India)
• Viatris Inc. (U.S.)
• Zydus Group (India)

Latest Developments in Global Oral Iron Therapy for Anemia Market

• In April 2025, Averoa announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) had issued a positive opinion for XOANACYL, an oral treatment for chronic kidney disease (CKD). This marks a significant milestone, bringing the therapy one step closer to potential approval in the European Union
• In March 2025, Kye Pharmaceuticals, Inc. announced the nationwide availability of ACCRUFeR (ferric maltol) in Canada. Approved as a prescription medication, ACCRUFeR is indicated for adult patients with iron deficiency anemia (IDA) who are either unresponsive to or unable to tolerate other oral iron therapies. Notably, ACCRUFeR is currently the only prescription-only oral treatment specifically approved for IDA in Canada
• In February 2023, the U.S. Food and Drug Administration approved Jesduvroq tablets (daprodustat) as the first oral therapy for treating anemia resulting from chronic kidney disease in adults who have been undergoing dialysis for a minimum of four months
• In December 2022, Shield Therapeutics plc announced the signing of an exclusive multi-year agreement with Viatris Inc. to co-commercialize Accrufer. As the only FDA-approved oral iron therapy for treating iron deficiency—with or without anemia—Accrufer stands out in the market. This strategic partnership aims to broaden Accrufer’s commercial reach and strengthen its market presence, supporting its ambition to become the preferred oral iron treatment in the U.S.
• In March 2022, Zydus Lifesciences Ltd. announced that it had received approval from the Drug Controller General of India for its New Drug Application (NDA) for Oxemia (Desidustat). Oxemia is the first oral treatment of its kind in India for managing anemia associated with chronic kidney disease (CKD). It is an oral, small-molecule hypoxia-inducible factor-prolyl hydroxylase (HIF-PH) inhibitor designed to address anemia in CKD patients

SKU-73793